NCT04315792View on ClinicalTrials.gov

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

January 25, 2021

Study Completion Date

August 25, 2021

Conditions
Bipolar I Disorder
Interventions
DRUG

Endoxifen

Administration of Endoxifen for 3 weeks

DRUG

Placebo oral tablet

Administration of Placebo for 3 weeks

Trial Locations (1)

33014

16420 NW 59 Avenue, Miami

Sponsors
All Listed Sponsors
collaborator

Novum Pharmaceutical Research Services

INDUSTRY

collaborator

Lambda Therapeutic Research Ltd.

INDUSTRY

lead

Jina Pharmaceuticals Inc.

INDUSTRY

NCT04315792 - Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients | Biotech Hunter | Biotech Hunter